Table 2 Adverse Events (≥ 5%) among Patients Receiving First-Line Multikinase Inhibitor Treatment
Sunitinib | Sorafenib | |||
|---|---|---|---|---|
(N = 85) | (N = 60) | |||
N (%) with adverse event | All grades | Grades 3/4 | All grades | Grades 3/4 |
Any adverse event | 83 (97.6) | 23 (27.1) | 42 (70.0) | 19 (31.7) |
Fatigue/Asthenia | 69 (81.2) | 8 (9.4) | 26 (43.3) | 6 (10.0) |
Mucositis/Stomatitis | 50 (58.8) | 2 (2.4) | 16 (26.7) | 0 (0.0) |
Hand-foot syndrome | 29 (34.1) | 2 (2.4) | 23 (38.3) | 2 (3.3) |
Diarrhea | 26 (30.6) | 0 (0.0) | 19 (31.7) | 2 (3.3) |
Hypertension | 35 (41.2) | 3 (3.5) | 6 (10.0) | 3 (5.0) |
Decreased taste sensation | 36 (42.4) | 0 (0.0) | 1 (1.7) | 0 (0.0) |
Abdominal pain | 19 (22.4) | 3 (3.5) | 10 (16.7) | 2 (3.3) |
Nausea | 25 (29.4) | 3 (3.5) | 2 (3.3) | 0 (0.0) |
Lack of appetite | 12 (14.1) | 0 (0.0) | 5 (8.3) | 1 (1.7) |
Pain | 13 (15.3) | 0 (0.0) | 4 (6.7) | 1 (1.7) |
Anorexia | 15 (17.6) | 5 (5.9) | 1 (1.7) | 0 (0.0) |
Vomiting | 15 (17.6) | 5 (5.9) | 1 (1.7) | 0 (0.0) |
Hemorrhage | 12 (14.1) | 0 (0.0) | 1 (1.7) | 0 (0.0) |
Constipation | 6 (7.1) | 0 (0.0) | 6 (10.0) | 1 (1.7) |
Edema | 12 (14.1) | 1 (1.2) | 0 (0.0) | 0 (0.0) |
Dermatitis | 6 (7.1) | 0 (0.0) | 4 (6.7) | 1 (1.7) |
Anemia | 5 (5.9) | 1 (1.2) | 3 (5.0) | 1 (1.7) |
Erythema | 7 (8.2) | 1 (1.2) | 1 (1.7) | 0 (0.0) |
Hypothyroidism | 6 (7.1) | 1 (1.2) | 2 (3.3) | 0 (0.0) |
Skin rash | 2 (2.4) | 0 (0.0) | 6 (10.0) | 2 (3.3) |
Dyspnea | 4 (4.7) | 0 (0.0) | 3 (5.0) | 2 (3.3) |
Hemorrhoids | 5 (5.9) | 0 (0.0) | 2 (3.3) | 0 (0.0) |
Alopecia | 1 (1.2) | 0 (0.0) | 4 (6.7) | 0 (0.0) |